Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases

Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases

March 14, 2017 Off By Dino Mustafić

AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.

In addition to this particular partnership, Ranedis has granted AMO an exclusive option to buy the global rights to RND-001 during the collaboration period. Terms of the deal were not disclosed.

“RND-001 is a promising therapy supported by compelling early stage research that gives Ranedis Pharmaceuticals and AMO Pharma an excellent opportunity to leverage known mechanisms in previously inaccessible rare diseases.  This collaboration represents an important next step in the expansion of our pipeline at AMO Pharma. RND-001 reflects many of the specific qualities we look for in asset acquisition, such as strong scientific rationale and opportunity to address unmet medical needs in rare diseases.  We will continue to target new opportunities that fit our strategic focus,” said Michael Snape, chief executive officer of AMO Pharma.

“The preclinical data have provided strong validation of the potential for RND-001 to uniquely address CNS symptoms in NPC and other rare diseases.  We are pleased that the development program will advance under this agreement with AMO Pharma,” said William Claypool, chief executive officer of Ranedis Pharmaceuticals.